Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

The market expects Alkermes (ALKS) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

Alkermes (ALKS-3.05%) proved to be a disappointment for investors last year, with its stock slipping while the overall market soared. However, the biotech is off to a pretty good start in 2021.

Alkermes plc (NASDAQ:ALKS) is one of the high-margin pharma stocks to buy now. Goldman Sachs has initiated coverage of ...

Alkermes says that after its 2020 “board-led transformation,” in which it “refreshed” 70% of its board, the company has improved its operations significantly. Related.